Santé log

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

The NDA resubmission is supported by results from the successful Phase 3 PIVOT-PO trial (NCT number – NCT06059846). The trial was stopped early for efficacy in May, 2025 following a planned interim ...
Santé log

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated ...
Santé log

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply ...

This change recognizes the medical use of cannabis and reduces barriers to research. MediPharm Labs is well positioned to benefit from this milestone through its FDA site registration, Drug ...
Santé log

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering ...
Santé log

Remedy's Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness

Remedy's Nutrition® maintains the highest quality standards in producing this premium multivitamin formula. Unlike mass-produced supplements, each batch undergoes rigorous testing for purity, potency, ...
Santé log

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application ...
Santé log

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

PL-16 is a metered-dose intranasal spray containing a hydrogel formulation composed of biodegradable polymers, together with standard excipients. Upon application, PL-16 forms a thin, muco-adhesive ...
Santé log

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

Total national coverage footprint for PENFS increases to roughly 100 million covered lives ...
Santé log

Sienna Completes Acquisition in the Greater Toronto Area

MARKHAM, Ontario, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed acquisition of a ...
Santé log

NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., Launches Brands PurrGuard® and Dog Gone Odor®, EPA-registered Odor-killing Bacteria Chemistry for ...

NDT Pharmaceuticals, Inc.’s (OTC: NDTP) wholly-owned subsidiary Good Salt Life, Inc., a pioneer in innovative surface treatment and biosecurity solutions, announces a groundbreaking achievement with ...
Santé log

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

The collaboration explores the effect of Amplia’s FAK inhibitors in combination with experimental drugs called kRas inhibitors Melbourne, Australia, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Amplia ...
Santé log

Glass House Brands Applauds Cannabis Reform Action

LONG BEACH, Calif. and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of ...